U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07944066) titled 'SGLT2 Inhibitor in Patients With Asymptomatic Moderate or Severe Aortic Stenosis' on Nov. 05.
Brief Summary: Aortic stenosis (AS) is the most common valvular heart disease, and no medical therapy has been shown to slow its progression; treatment is limited to surgical or transcatheter aortic valve replacement once symptoms or left ventricular dysfunction develop. Sodium-glucose cotransporter-2 (SGLT2) inhibitors reduce cardiovascular death and heart failure hospitalization in patients with and without diabetes, and preclinical studies show that they suppress the inflammatory (NLRP3 inflammasome), fibrotic (TGF-beta/Smad), and oxidat...